Ernexa Therapeutics (NASDAQ:ERNA) Posts Earnings Results

Posted by Andrew Walz on Mar 14th, 2026

Ernexa Therapeutics (NASDAQ:ERNA – Get Free Report) issued its quarterly earnings results on Friday. The company reported ($0.01) earnings per share for the quarter, Zacks reports.

Ernexa Therapeutics Price Performance

Shares of Ernexa Therapeutics stock traded up $0.02 during trading hours on Friday, reaching $0.32. The company’s stock had a trading volume of 3,433,063 shares, compared to its average volume of 3,604,398. The stock has a market cap of $2.54 million, a P/E ratio of -0.11 and a beta of 6.58. Ernexa Therapeutics has a one year low of $0.27 and a one year high of $4.20. The firm has a 50 day moving average price of $0.73 and a 200-day moving average price of $1.12.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Ernexa Therapeutics stock. Susquehanna International Group LLP bought a new stake in shares of Ernexa Therapeutics Inc. (NASDAQ:ERNA – Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned 0.39% of Ernexa Therapeutics at the end of the most recent quarter. 70.55% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Ernexa Therapeutics in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Ernexa Therapeutics has an average rating of “Sell”.

Check Out Our Latest Report on ERNA

Ernexa Therapeutics Company Profile

(Get Free Report)

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.